ROCHESTER, Minn. -- The primary treatment for wet macular degeneration, a chronic eye condition that causes vision loss, is effective even if patients have macular traction problems, a Mayo Clinic study shows. The findings will be presented today at the annual meeting of the American Academy of Ophthalmology in Chicago.
Culture
WASHINGTON -- Refuting a belief long held by many physicians, a Mayo Clinic study found that rheumatoid arthritis patients also can get gout. The research is among several studies Mayo Clinic is presenting at the American College of Rheumatology annual meeting in Washington.
WASHINGTON -- Patients who make $35,000 a year or less report better outcomes after knee replacement surgery than people who earn more, research by Mayo Clinic and the University of Alabama at Birmingham shows. The lower-income patients studied reported less pain and better knee function at their two-year checkups than wealthier people did. The study was being presented at the American College of Rheumatology annual meeting in Washington.
VIDEO ALERT: A video interview with Dr. Lewallen is available for journalists to downloadon the Mayo Clinic News Network.
After total knee replacement (TKR) surgery, patients who are morbidly obese have similar pain and function outcomes as patients who do not fall into this weight category, according to a new study by researchers at Hospital for Special Surgery. The finding is surprising given that numerous studies have shown that obese patients have worse outcomes. The study will be reported at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, to be held Nov. 9-14, in Washington D.C.
A low-cost exercise program run by Hospital for Special Surgery in New York City has significantly improved pain, function and quality of life in participants with osteoarthritis, according to new research.
The study adds to the growing evidence that exercise is beneficial for osteoarthritis and shows that a hospital-based program can work. The study will be reported at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held Nov. 9-14, in Washington D.C.
A design student from Russia has decided to capitalize on the furor over punk band Pussy Riot in her homeland by creating a...tea set.
Muscovite Alina Tukhvatullina, 24, who has just completed an MA in design at London’s Kingston University, has designed what appears to be a traditional Russian tea set, but hidden among the Khokhloma floral patterns are the names of topics that are generating controversy in modern day Russia.
Immunomic Therapeutics, Inc., a clinical stage biotechnology company, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax™ vaccine, at its clinical site in Honolulu, Hawaii.
The humanized antibody ipilimumab (trade name Yervoy®) has been approved since August 2011 for the treatment of adult patients with advanced melanoma (black skin cancer) who have already been treated. The term "advanced" means that the melanoma can no longer be removed by an operation or that metastases have formed. The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG).
Vandetanib (trade name Caprelsa®) has been approved in Germany since February 2012 for adult patients suffering from a particular form of aggressive thyroid cancer. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, there is no proof of added benefit, because no data on patient-relevant outcomes for those patients for whom the drug is approved were presented by the drug manufacturer in its dossier.
ANAHEIM, CA. (November 9, 2012) – Peanut allergies are rising among American children and one reason might be due to economic status. According to a new study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, greater rates of peanut allergy are found in families with higher economic status. This supports the "hygiene hypothesis" of many allergists.
ANAHEIM, CA. (November 9, 2012) – While it's believed that Nostradamus' prophecies predicted many historical events, his digital successor, the Internet, may be foreseeing the height of allergy suffering. According to allergist Leonard Bielory, M.D., American College of Allergy, Asthma and Immunology (ACAAI) board member, Google search volume is shedding light on the most common allergy symptoms, when searches peak and how they pertain to pollen types.
Twitter, a popular social network and microblogging service, is rapidly being adopted by allergists. A study presented at the American College of Allergy, Asthma and Immunology's (ACAAI) Annual Scientific Meeting in Anaheim, Calif. Nov. 8-13 has found there has been a 470 percent increase in allergist use in just one year. Allergists are primarily using Twitter to educate their patients and the public about allergy-related information. They are also connecting with their peers.
Title: Rapid Growth of Twitter Use by Allergists and Immunologists for Professional Purposes
Epinephrine is the first line of treatment for patients suffering from anaphylaxis, a life-threatening allergic reaction. A delay in using epinephrine is common in severe food allergic reaction deaths. Yet according to a new study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, Calif. Nov. 8-13, only 15 percent of those experiencing anaphylaxis receive epinephrine from paramedics.
Analysis: Stop the silent misdiagnosis: Patients' preferences matter
Patients' preferences are often misinterpreted or ignored in treatment decisions, leading to a "silent misdiagnosis" that is damaging to both doctors and patients, warn experts on bmj.com today.
Preliminary findings from the first trial of a new drug for patients with mesothelioma show that it has some success in preventing the spread of the deadly disease in patients lacking an active tumour suppressor gene called NF2. The study is presented at the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Friday) [2].